OnKure Q1 net loss $15.9M, cash $96.7M; PIKture-01 trial on track for H2 2025 data

OnKure Therapeutics, Inc.

2025-Q1 EPS reported -$1.19

Net loss of $15.9M ($1.19 per share) vs $9.5M in Q1 2024; R&D expense rose to $13.0M.
Cash and cash equivalents of $96.7M expected to fund operations into Q4 2026.
PIKture-01 Part A monotherapy enrollment closed; mature data expected H2 2025.
Part B fulvestrant combo dose escalation nearing completion; initial data in H2 2025.
Pan-mutant PI3Kα development candidate to be announced in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.